Company: STAA
Filing Date: 2025-09-02
Form Type: DEFA14A
Source: 0001193125-25-194146
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-09-02
Form: DEFA14A
Chunk 1
---
 trends have been declining despite actions taken by the Company. Notably, STAAR’s common stock closed at $18.49 per share on the trading day prior to the announcement of the Alcon agreement.

The merger agreement includes provisions that are highly favorable to STAAR stockholders and were extensively negotiated by the Company to
further its value-maximizing objective.

We look forward to engaging with our stockholders on the merits of the Alcon merger and why the
STAAR Board of Directors unanimously believes it is in the best interest of all STAAR stockholders.”

About STAAR Surgical

STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need
for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICL’s are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the
eye’s natural crystalline lens. Its EVO ICL product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75
countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit www.EVOICL.com. To learn more about STAAR,
visit www.staar.com.

Additional Information About the Merger and Where to Find It

This communication relates to the proposed transaction involving STAAR. In connection with the proposed transaction, STAAR has filed relevant materials with
the U.S. Securities and Exchange Commission (the “SEC”), including STAAR’s preliminary proxy statement on Schedule 14A, and will file a definitive proxy statement on Schedule 14A (the “Proxy Statement”). This
communication is not a substitute for the Proxy Statement or any other document that STAAR may file with the SEC or send to its stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF STAAR ARE
URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS